EUCTR2007-002478-76-CZ进行中（未招募）1 期
Clinical study phase III evaluating the efficacy of Diffusil H Forte spray
ybar a.s.0 个研究点目标入组 110 人开始时间: 2007年5月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a)patients with pediculosis confirmed by a positive dry combing test at Visit 1
- •b)patients able and willing to give written informed consent
- •c)patients able and willing to comply with the requirements of the study
- •d)feasibility of the dry combing test
- •e)age 18- 70 years, male and female
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)any scalp condition that makes impossible the feasibility of the dry combing test
- •b)acute conjunctivitis
- •c)clinical signs of eczema exacerbation
- •d)contact eczema in anamnesis
- •e)history of severe allergic or anaphylactic reactions to any ingredients of the tested products
- •f)history of sensitivity to hair shampoo and conditioners
- •g)previous treatment with anti-lice products 2 weeks prior to Visit 1
- •h)concomitant treatment influencing the evaluation of efficacy such as use of trimethoprim or cotrimoxazol within 4 weeks prior to Visit 1
- •i)use of antihistaminics within 3 days prior Visit 1
- •j)participating in another clinical trial within 4 weeks prior to Visit 1
- •k)pregnancy or breast-feeding
- •l)hairdressing such as bleaches, perm or dying
研究者
相似试验
进行中（未招募）
3 期
A Phase III clinical study of LF111 in Japanese women desiring contraceptioJPRN-jRCT2031210556Kikuyama Ryoko260
进行中（未招募）
3 期
A phase III clinical study in patients with active rheumatoid arthritis who show an inadequate response or intolerance to previous or current treatmentRheumatoid ArthritisJPRN-jRCT2011220026Okugaito Izumi113
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-FIMSD Finland20,300
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-DEMerck & Co., Inc.20,300
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age. - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-BEMerck Sharp & Dohme BV20,300